-
Product Insights
Fore River Power Plant
Fore River Power Plant is a thermal project located in Massachusetts, United States. The project is owned by Calpine Corp. The project came online in 2003. Empower your strategies with our Fore River Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plixorafenib in Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plixorafenib in Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plixorafenib in Glioma Drug Details: FORE-8394 (PLX-8394) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plixorafenib in Low-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plixorafenib in Low-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plixorafenib in Low-Grade Glioma Drug Details: FORE-8394 (PLX-8394) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FORE-8394 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FORE-8394 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plixorafenib in Solid Tumor Drug Details: FORE-8394 (PLX-8394) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Amyloidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Amyloidosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Amyloidosis Drug Details: Venetoclax (ABT-199, GDC-0199/RG7601, Venclexta, Venclyxto) acts as...
-
Product Insights
Oligodendroglioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Oligodendroglioma - Drugs In Development, 2023’, provides an overview of the Oligodendroglioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Oligodendroglioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Low-Grade Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Low-Grade Glioma - Drugs In Development, 2023’, provides an overview of the Low-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Low-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Anaplastic Astrocytoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Anaplastic Astrocytoma - Drugs In Development, 2023’, provides an overview of the Anaplastic Astrocytoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gliosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Gliosarcoma - Drugs In Development, 2023’, provides an overview of the Gliosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gliosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
High-Grade Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘High-Grade Glioma - Drugs In Development, 2023’, provides an overview of the High-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...